Polyrizon (NASDAQ:PLRZ) announced the successful preliminary safety study of a formulation of its PL-14 Allergy Blocker, advancing the product’s development path.
According to Polyrizon, the study, designed to assess tolerance and tissue response following a 4-hour application of its mucoadhesive nasal gel spray formulation of PL-14 Allergy Blocker, was conducted on fully differentiated human nasal tissue using the MucilAir model. The data serve as a key step in the company’s regulatory strategy and will support its upcoming FDA pre-submission meeting. U.S. and EU clinical trials are expected to commence in late 2025 or early 2026.
In a statement, Tomer Izraeli, CEO of Polyrizon, said, “These results represent an important milestone in validating the local safety of a formulation of PL-14 3D polymeric network and provide foundational support for advancing our clinical development. Our goal is to offer a drug-free, well-tolerated nasal spray that provides daily protection against airborne allergens by forming a stable physical barrier in the nasal cavity.”
